Andrew S. Kao , Jonathan Kermanshahchi , Shamim Khosrowjerdi , Alexander C. Razavi , Jacqueline Levene , Mikaila Reyes , Parveen Garg , W.T. Longstreth Jr. , Kristiina Rannikmae , Cathie Sudlow , Michael Tsai , Sotirios Tsimikas , Anum Saeed , Harpreet S. Bhatia
{"title":"脂蛋白(a)和中风的人口统计数据:英国生物银行","authors":"Andrew S. Kao , Jonathan Kermanshahchi , Shamim Khosrowjerdi , Alexander C. Razavi , Jacqueline Levene , Mikaila Reyes , Parveen Garg , W.T. Longstreth Jr. , Kristiina Rannikmae , Cathie Sudlow , Michael Tsai , Sotirios Tsimikas , Anum Saeed , Harpreet S. Bhatia","doi":"10.1016/j.ajpc.2025.101055","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Lipoprotein(a) [Lp(a)] is associated with ischemic stroke, but the strength of association based on demographic differences remains unclear. We aimed to investigate the association between Lp(a)>125 nmol/L and stroke by age, sex, and racial/ethnic subgroups.</div></div><div><h3>Methods</h3><div>Using data from the UK Biobank, we included 353,309 participants with an Lp(a) measurement without a history of atherosclerotic cardiovascular disease (ASCVD). Stroke was defined as ischemic stroke or hemorrhagic stroke (with subtypes subarachnoid hemorrhage and intracerebral hemorrhage). Cox proportional hazards models were used to evaluate the association between elevated Lp(a) and stroke (ischemic or hemorrhagic), adjusted for ASCVD risk factors, race/ethnicity, lipid lowering therapy, antiplatelet and anticoagulation medications. Outcomes were defined using ICD-10 codes.</div></div><div><h3>Results</h3><div>The study population consisted of 55.7 % women and 94 % White individuals with average age of 56 years. The median Lp(a) level was 20.9 [IQR 9.5, 61.4] nmol/L and prevalence of Lp(a) >125 nmol/L was 11.1 % (<em>n</em> = 39,067). Over a median follow-up of 13.8 [13.1, 14.5] years, there were 5002 (1.4 %) ischemic strokes and 1462 (0.4 %) hemorrhagic strokes. Lp(a) > 125 nmol/L was associated with increased risk for ischemic stroke (HR 1.12, 95 % CI 1.02–1.22, <em>P</em> = 0.019), but not hemorrhagic stroke (HR 0.95, 95 % CI 0.79–1.13, <em>P</em> = 0.545). The association between Lp(a)>125 nmol/L and ischemic stroke did not vary by age (p-interaction=0.691) or race/ethnicity (p-interaction 0.526) but did vary by sex (p-interaction=0.041) with an association among men (HR 1.20, 95 % CI 1.07–1.36) but not among women.</div></div><div><h3>Conclusion</h3><div>Lp(a) is independently associated with ischemic stroke, with variation by sex but not age or race/ethnicity. Lp(a) was not significantly associated with hemorrhagic stroke.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"23 ","pages":"Article 101055"},"PeriodicalIF":5.9000,"publicationDate":"2025-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Demographics of lipoprotein(a) and stroke: The UK biobank\",\"authors\":\"Andrew S. Kao , Jonathan Kermanshahchi , Shamim Khosrowjerdi , Alexander C. Razavi , Jacqueline Levene , Mikaila Reyes , Parveen Garg , W.T. Longstreth Jr. , Kristiina Rannikmae , Cathie Sudlow , Michael Tsai , Sotirios Tsimikas , Anum Saeed , Harpreet S. Bhatia\",\"doi\":\"10.1016/j.ajpc.2025.101055\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>Lipoprotein(a) [Lp(a)] is associated with ischemic stroke, but the strength of association based on demographic differences remains unclear. We aimed to investigate the association between Lp(a)>125 nmol/L and stroke by age, sex, and racial/ethnic subgroups.</div></div><div><h3>Methods</h3><div>Using data from the UK Biobank, we included 353,309 participants with an Lp(a) measurement without a history of atherosclerotic cardiovascular disease (ASCVD). Stroke was defined as ischemic stroke or hemorrhagic stroke (with subtypes subarachnoid hemorrhage and intracerebral hemorrhage). Cox proportional hazards models were used to evaluate the association between elevated Lp(a) and stroke (ischemic or hemorrhagic), adjusted for ASCVD risk factors, race/ethnicity, lipid lowering therapy, antiplatelet and anticoagulation medications. Outcomes were defined using ICD-10 codes.</div></div><div><h3>Results</h3><div>The study population consisted of 55.7 % women and 94 % White individuals with average age of 56 years. The median Lp(a) level was 20.9 [IQR 9.5, 61.4] nmol/L and prevalence of Lp(a) >125 nmol/L was 11.1 % (<em>n</em> = 39,067). Over a median follow-up of 13.8 [13.1, 14.5] years, there were 5002 (1.4 %) ischemic strokes and 1462 (0.4 %) hemorrhagic strokes. Lp(a) > 125 nmol/L was associated with increased risk for ischemic stroke (HR 1.12, 95 % CI 1.02–1.22, <em>P</em> = 0.019), but not hemorrhagic stroke (HR 0.95, 95 % CI 0.79–1.13, <em>P</em> = 0.545). The association between Lp(a)>125 nmol/L and ischemic stroke did not vary by age (p-interaction=0.691) or race/ethnicity (p-interaction 0.526) but did vary by sex (p-interaction=0.041) with an association among men (HR 1.20, 95 % CI 1.07–1.36) but not among women.</div></div><div><h3>Conclusion</h3><div>Lp(a) is independently associated with ischemic stroke, with variation by sex but not age or race/ethnicity. Lp(a) was not significantly associated with hemorrhagic stroke.</div></div>\",\"PeriodicalId\":72173,\"journal\":{\"name\":\"American journal of preventive cardiology\",\"volume\":\"23 \",\"pages\":\"Article 101055\"},\"PeriodicalIF\":5.9000,\"publicationDate\":\"2025-06-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of preventive cardiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666667725001308\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of preventive cardiology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666667725001308","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
脂蛋白(a) [Lp(a)]与缺血性卒中相关,但基于人口统计学差异的关联强度尚不清楚。我们的目的是调查Lp(a)>;125 nmol/L与中风之间的关系,并按年龄、性别和种族/民族亚组进行分类。方法使用英国生物银行的数据,我们纳入了353309名无动脉粥样硬化性心血管疾病(ASCVD)史的Lp(a)测量参与者。卒中定义为缺血性卒中或出血性卒中(蛛网膜下腔出血和脑出血亚型)。Cox比例风险模型用于评估Lp(a)升高与卒中(缺血性或出血性)之间的关系,并根据ASCVD危险因素、种族/民族、降脂治疗、抗血小板和抗凝药物进行调整。使用ICD-10代码定义结果。结果研究人群中女性55.7%,白人94%,平均年龄56岁。中位Lp(a)水平为20.9 [IQR 9.5, 61.4] nmol/L, Lp(a) >;125 nmol/L患病率为11.1% (n = 39,067)。在中位随访13.8年[13.1,14.5]年期间,有5002例(1.4%)缺血性卒中和1462例(0.4%)出血性卒中。Lp (a)在125 nmol/L与缺血性卒中风险增加相关(HR 1.12, 95% CI 1.02-1.22, P = 0.019),但与出血性卒中无关(HR 0.95, 95% CI 0.79-1.13, P = 0.545)。Lp(a)>;125 nmol/L与缺血性卒中之间的相关性不受年龄(p-相互作用=0.691)或种族/民族(p-相互作用0.526)的影响,但受性别(p-相互作用=0.041)的影响(HR 1.20, 95% CI 1.07-1.36),但在女性中无相关性。结论Lp(a)与缺血性卒中独立相关,与性别有关,而与年龄或种族/民族无关。Lp(a)与出血性卒中无显著相关性。
Demographics of lipoprotein(a) and stroke: The UK biobank
Introduction
Lipoprotein(a) [Lp(a)] is associated with ischemic stroke, but the strength of association based on demographic differences remains unclear. We aimed to investigate the association between Lp(a)>125 nmol/L and stroke by age, sex, and racial/ethnic subgroups.
Methods
Using data from the UK Biobank, we included 353,309 participants with an Lp(a) measurement without a history of atherosclerotic cardiovascular disease (ASCVD). Stroke was defined as ischemic stroke or hemorrhagic stroke (with subtypes subarachnoid hemorrhage and intracerebral hemorrhage). Cox proportional hazards models were used to evaluate the association between elevated Lp(a) and stroke (ischemic or hemorrhagic), adjusted for ASCVD risk factors, race/ethnicity, lipid lowering therapy, antiplatelet and anticoagulation medications. Outcomes were defined using ICD-10 codes.
Results
The study population consisted of 55.7 % women and 94 % White individuals with average age of 56 years. The median Lp(a) level was 20.9 [IQR 9.5, 61.4] nmol/L and prevalence of Lp(a) >125 nmol/L was 11.1 % (n = 39,067). Over a median follow-up of 13.8 [13.1, 14.5] years, there were 5002 (1.4 %) ischemic strokes and 1462 (0.4 %) hemorrhagic strokes. Lp(a) > 125 nmol/L was associated with increased risk for ischemic stroke (HR 1.12, 95 % CI 1.02–1.22, P = 0.019), but not hemorrhagic stroke (HR 0.95, 95 % CI 0.79–1.13, P = 0.545). The association between Lp(a)>125 nmol/L and ischemic stroke did not vary by age (p-interaction=0.691) or race/ethnicity (p-interaction 0.526) but did vary by sex (p-interaction=0.041) with an association among men (HR 1.20, 95 % CI 1.07–1.36) but not among women.
Conclusion
Lp(a) is independently associated with ischemic stroke, with variation by sex but not age or race/ethnicity. Lp(a) was not significantly associated with hemorrhagic stroke.